Intranasal calcitonin was given as a positive control in the trial. Nasal calcitonin is already a registered product in a number of countries and has been shown to be effective in the treatment of osteoporosis. No serious side effects were observed in any treatment group. The statistical analyses, have also yielded information which will be very useful for our USA program. The broader implications for Cortecs relate to the potential for applying the oral delivery technologies to other macromolecules.
Osteoporosis is a very common disease.
At least 200 million people worldwide suffer from the disease. Almost half of all women will have bone fractures related to the disease by the time they reach 70. About one fifth of those with hip fractures, a result of osteoporosis, die from conditions related to the fracture itself or as a result of related surgery. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.